EUCTR2019-004862-16-PL进行中（未招募）1 期
A Phase 2, MulticEntre, Double-Blind, THree-Arm, Placebo and Active Control Efficacy andSafetY STudy to Evaluate Verinurad combined with Allopurinol in Heart Failure withPreserved Ejection Fraction - AMETHYST
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 435
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Patient must be = 40 years of age at the time of signing the ICF
- •- Patients with hyperuricaemia defined as sUA level of > 6 mg/dL.
- •- Patients with documented diagnosis of symptomatic HFpEF according to all of the
- •following criteria:
- •(a) Have NYHA functional class II-III at enrolment
- •(b) Have medical history of typical symptoms/signs of HF > 6 weeks before enrolment
- •(c) LVEF = 45%
- •(d) NT-proBNP = 125 pg/mL (= 14.75 pmol/L) at Visit 2 for patients without ongoing
- •atrial fibrillation/flutter.
- •- Patients able to exercise to near exhaustion during a CPET as exhibited by RER
- •= 1.05 during CPET conducted during screening. If patient does not achieve RER = 1.05 the CPET may be repeated once, at least 48 hours but less than 2 weeks (but before
- •randomisation) after the initial test; in such cases the second test will serve as baseline.
- •- Male or female
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 131
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 304
排除标准
- •- eGFR < 30ml/min/1.73m2 (based on CKD-EPI formula)
- •- Severe hepatic impairment (Child-Pugh class C)
- •- Presence of any condition that precludes exercise testing
- •- Known history of a documented LVEF < 40%
- •- Probable alternative or concomitant diagnoses which in the opinion of the Investigator
- •could account for the patient's HF symptoms and signs (eg, anaemia, hypothyroidism)
- •- Known carrier of the HLA-B *58:01 allele. Patients of suspected Han Chinese, Korean or
- •Thai descent, and patients from populations in whom the HLA*B58:01 allele is known to
- •be high shall perform genetical testing, for others the genetic test is at the discretion of the
- •investigator
- •- Patients diagnosed with tumor lysis syndrome or Lesch-Nyhan syndrome
- •- Patients who are severely physically or mentally incapacitated and who in the opinion of
- •investigator are unable to perform the patients’ tasks associated with the protocol
- •- Presence of any condition which, in the opinion of the investigator, places the patient at
- •undue risk or potentially jeopardises the quality of the data to be generated
- •- Current acute decompensated HF or hospitalisation due to decompensated HF < 4 weeks
- •prior to enrolment
- •- Myocardial infarction, unstable angina, coronary revascularisation (percutaneous
- •coronary intervention or coronary artery bypass grafting), ablation of atrial
- •flutter/fibrillation, valve repair/replacement, implantation of a cardiac resynchronisation
- •therapy device, stroke or transient ischemic attack within 6 months prior to enrolment.
- •- Planned coronary revascularisation, ablation of atrial flutter/fibrillation and/or valve
- •repair/replacement
- •- Atrial fibrillation with persistent resting heart rate > 110 beats per minute.
研究者
相似试验
进行中（未招募）
1 期
Study of verinurad and allopurinol in heart failure with preserved ejection fractioHeart Failure Patients with Preserved Ejection Fraction (HFpEF) and hyperuricaemiaMedDRA version: 20.1Level: LLTClassification code 10076396Term: Heart failure with preserved ejection fractionSystem Organ Class: 100000004849EUCTR2019-004862-16-SKAstraZeneca AB150
进行中（未招募）
不适用
A Multicenter, Double-Blind, 3-Arm, Phase 1b/2 Study in Subjects with UnresectableLocally Advanced or Metastatic Gastric or Esophagogastric Junction Adenocarcinoma to Evaluate the Safety and Efficacy of First-line Treatment with Epirubicin, Cisplatin, and Capecitabine(ECX) plus AMG 102nrespectable locally advanced or metastatic gastric or esophagogastric junction adenocarcinomaEUCTR2008-001605-42-GRAmgen Inc138
进行中（未招募）
不适用
A Multicenter, Double-Blind, 3-Arm, Phase 1b/2 Study in Subjects with Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Adenocarcinoma to Evaluate the Safety and Efficacy of First-line Treatment with Epirubicin, Cisplatin, and Capecitabine(ECX) plus AMG 102 - 20060317Previously untreated subjects with unresectable locally advanced or metastatic gastric or esophagogastric junction adenocarcinoma.MedDRA version: 9.1Level: LLTClassification code 10051635Term: Gastrointestinal tract adenomaEUCTR2008-001605-42-ITAmgen Inc138
进行中（未招募）
1 期
AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancernrespectable locally advanced or metastatic gastric or esophagogastric unction adenocarcinomaMedDRA version: 14.1 Level: LLT Classification code 10017759 Term: Gastric cancer in situ System Organ Class: 100000004864EUCTR2008-001605-42-GBAmgen Inc138
进行中（未招募）
不适用
A Multicenter, Double-Blind, 3-Arm, Phase 1b/2 Study in Subjects with UnresectableLocally Advanced or Metastatic Gastric or Esophagogastric Junction Adenocarcinoma to Evaluate the Safety and Efficacy of First-line Treatment with Epirubicin, Cisplatin, and Capecitabine(ECX) plus AMG 102.-----------------------------------------------------------Estudio multicéntrico, a doble ciego, de 3 brazos y de fases 1b/2 en sujetos con adenocarcinoma gástrico o de la unión gastroesofágica metastásico o localmente avanzado no resecable para evaluar la seguridad y la eficacia del tratamiento de primera línea con epirubicina, cisplatino y capecitabina (ECX) junto con AMG 102.nrespectable locally advanced or metastatic gastric or esophagogastric unction adenocarcinoma.-----------------------------------------------------------Sujetos con adenocarcinoma gástrico o de la unión gastroesofágica metastásico o localmente avanzado no resecable, no tratados previamenteEUCTR2008-001605-42-ESAmgen Inc138